Antifibrotic drug finerenone restores fertility in premature ovarian insufficiency
University of Hong Kong - Shenzhen Hospital · University of Hong Kong · +4 more institutions
Abstract
Currently, no effective treatment exists for infertility associated with premature ovarian insufficiency (POI) because affected patients lack hormone-responsive antral follicles. By screening a Food and Drug Administration (FDA)-approved drug library, we identified finerenone, a kidney disease medication, as a promising drug for restoring fertility in POI. Finerenone stimulated follicle development in aged mice and restored antral follicle development in patients with POI following oral administration, resulting in mature oocytes and embryos. Mechanistically, finerenone reduced fibrotic deposition in the ovarian stroma, alleviating collagen-mediated suppression of follicular development. Building on this…
Citation impact
- FWCI
- 79.71
- Percentile
- 99%
- References
- 51
Authors
32- ZLZexiong LinCorresponding
University of Hong Kong - Shenzhen Hospital, University of Hong Kong
- YLYuan LiCorresponding
University of Hong Kong - Shenzhen Hospital, University of Hong Kong
- YLYuan Li
University of Hong Kong - Shenzhen Hospital, University of Hong Kong
- YZYu ZhaoCorresponding
University of Hong Kong - Shenzhen Hospital, University of Hong Kong
- DLDongteng LiuCorresponding
University of Hong Kong
Topics & keywords
- Premature ovarian insufficiency
- Infertility
- Drug
- Premature ovarian failure
- Antral follicle
- Follicular phase
- Fertility
- Ovarian follicle